Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
anitocabtagene autoleucel (CART-ddBCMA) / Arcellx, Gilead
iMMagine-3, NCT06413498: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma	Not yet recruiting	3	450	NA	Anitocabtagene Autoleucel, CART-ddBCMA, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib	Kite, A Gilead Company, Arcellx, Inc.	Multiple Myeloma	07/28	07/31
iMMagine-1, NCT05396885: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma	Recruiting	2	110	US	anitocabtagene-autoleucel, CART-ddBCMA	Kite, A Gilead Company, Arcellx, Inc.	Multiple Myeloma	05/24	05/25
ARC-101, NCT04155749: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma	Recruiting	1	65	US	anitocabtagene-autoleucel, ARC-T Plus Anti-BCMA SparX	Kite, A Gilead Company, Arcellx, Inc.	Relapsed and Refractory Multiple Myeloma	08/24	11/35